Encouraging news for patients with triple negative breast cancer

Encouraging news for patients with triple negative breast cancer

Encouraging news for patients with triple negative breast cancer from a phase III immunotherapy study (IMpassion 130). „The combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) as first-line treatment significantly reduced the risk of disease worsening or death in patients with metastatic or unresectable locally advanced triple-negative breast cancer“.

https://de-de.facebook.com/permalink.php?story_fbid=1869551873137690&id=414100488682843

IMpassion130: Atezolizumab Plus Nab-Paclitaxel in Metastatic or Locally Advanced Triple-Negative Breast Cancer – The ASCO Post

The phase III IMpassion130 study has met its co-primary endpoint of progression-free survival (PFS). Results demonstrated that the combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) as first-line treatment significantly reduced the risk of disease worsening or death in patients with metastatic or unresectable locally advanced triple-negative breast cancer. Overall survival (OS) is encouraging…

http://www.ascopost.com/News/59027

Leave a Reply

Your email address will not be published. Required fields are marked *